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ABSTRACT - OBJECTIVES: This study aimed to systematically review and quantitatively synthesize the 
association between HLA-B*5701 and abacavir-induced hypersensitivity reaction (ABC-HSR). 
METHODS: We searched for studies that investigated the association between HLA-B genotype and ABC-
HSR and provided information about the frequency of carriers of HLA-B genotypes among cases and 
controls. We then performed a meta-analysis with a random-effects model to pool the data and to investigate 
the sources of heterogeneity. RESULTS: From 1,026 articles identified, ten studies were included. Five 
using clinical manifestation as their diagnostic criteria, 409 and 1,883 subjects were included as cases and 
controls. Overall OR was 23.6 (95% CI = 15.4 – 36.3). Whereas, the another five studies using confirmed 
immunologic test as their diagnostic criteria, 110 and 1,968 subjects were included as cases and controls, 
respectively. The association of ABC-HSR was strong in this populations with HLA-B*5701. Overall OR 
was 1,056.2 (95% CI = 345.0 – 3,233.3). CONCLUSIONS: Using meta-analysis technique, the association 
between HLA-B*5701 and ABC-HSR is strong in the studies using immunologic confirmation to identify 
ABC-HSR. These results support the US FDA recommendations for screening HLA-B*5701 allele before 
initiating abacavir therapy.   
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
____________________________________________________________________ 
 
INTRODUCTION 
 
Abacavir is a nucleoside reverse transcriptase 
inhibitor (NRTI) commonly co-prescribed with 
other antiretroviral agents in the treatment of HIV 
infection (1). However, abacavir-induced 
hypersensitivity reaction (ABC-HSR) is a major 
problem in abacavir pharmacotherapy (2). 
Approximately 5-8% of patients initiating 
abacavir treatment can develop HSR within the 
first 4-6 weeks (3-5). Symptoms of ABC-HSR are 
a multi-organ syndrome characterized by two or 
more clinical signs: fever, rash, gastrointestinal 
symptoms and respiratory symptoms (5). 
HLA-B*5701, a specific human leukocyte 
antigen (HLA) allele, has been shown to represent 
the strongest predictor of ABC-HSR (4,6). HLAs 
are a set of genes that encode major 
histocompatibility complex (MHC), a group of 
proteins that have potential roles in the immune 
system (7,8). Abacavir binds specifically to the 
HLA-B*5701 protein at its ‘F-pocket’. This 
binding results in the formation of a protein 
complex recognized as a foreign body, which 
triggers an autoimmune activation by CD8+T-
cells. The outcome of this autoimmune activation 
is ABC-HSR (9-11).  
The association between HLA-B*5701 and 
ABC-HSR was extensively studied in several 
epidemiological studies (3,12-15). In 2008, the 
US Food and Drug Administration recommended 
a HLA-B*5701 screening test for all patients 
prior to starting abacavir (5). However, among the 
published studies, the reported odds ratios showed 
extreme variation, from 0 to ~7,000 (4,14-17).  
Such variation might be due to the differences 
between study populations, methods used to 
diagnose ABC-HSR, and many other factors.  
The present study aimed to use a systematic 
review and meta-analysis approach to elucidate  
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 the multiple factors which affect the extent of 
association between HLA-B*5701 genotype and 
ABC-HSR. 
 
METHODS 
 
Search Strategy and Study Selection 
We performed a systematic search in 6 databases 
[PubMed, Embase, Cumulative Index to Nursing 
and Allied Health Literature (CINAHL), 
International Pharmaceutical Abstracts (IPA), 
Human Genome Epidemiology Network 
(HuGENet), and Cochrane library] from their 
inception until September of 2014 using 
keywords and relevant terms for “HLA-B*5701 
genotypes”, “abacavir-induced”, and 
“hypersensitivity”.  There was no restriction on 
language or study design.  We included reports  in 
which (i) the association between the HLA-
B*5701 genotype and ABC-HSR was 
investigated; (ii) all patients in both case and 
control group had received abacavir; (iii) the use 
of abacavir was irrelevant to HLA-B*5701 
screening, and; (iv) sufficient data for calculating 
frequency of carriers of the HLA-B*5701 among 
both cases and controls were reported. Our 
procedure in the systematic review and meta-
analysis is shown in Figure1. If two or more 
studies shared the same patient population, the 
study with more complete data or a larger sample 
size was included. For the studies which met the 
inclusion criteria but did not provide sufficient 
data for meta-analysis, the corresponding authors 
were asked to provide additional information. 
Studies were also retrieved from the references 
listed in the selected articles. 
 
 
Figure 1 - Flow diagram of study selection process 
 
Data Extraction and Quality Assessment 
The relevant information from the selected 
articles was independently extracted as follows: 
study design, eligibility criteria, definition and 
diagnostic criteria for the cases and controls, 
patient demographics, dose and duration of 
abacavir exposure, method used to diagnose a 
ABC-HSR (i.e., clinical evaluation with or 
without confirmatory immunological testing), and 
the HLA genotyping technique. Genotype 
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frequencies of HLA-B*5701 were calculated to 
determine whether the included populations were 
in Hardy-Weinberg equilibrium (HWE) (18,19). 
HWE implies that the included individuals are 
likely to be representative of the population 
(20,21). The Newcastle-Ottawa scale (NOS) 
comprising three domains including selection, 
comparability, and outcome or exposure was used 
to assess the quality of the included studies (22).  
Two reviewers (WT and OL) independently 
selected the articles, extracted the data, and 
performed the study quality assessment. Any 
disagreement was discussed until consensus was 
reached between both reviewers. 
 
DATA ANALYSIS 
 
In a routine clinical setting, ABC-HSR is 
diagnosed by a clinical evaluation with or without 
immunologic confirmation (skin patch test). 
However, the diagnostic accuracy of both 
methods was clearly different. Since the 
sensitivity of immunologic confirmation was 
much higher than that of clinical evaluation (0.98 
vs. 0.40) the diagnosis when using immunologic 
confirmation would be more reliable (23). Thus, 
we performed separate analyses of data sets 
obtained from the different diagnostic methods. 
The overall ORs with corresponding 95% 
confidence intervals (95% CIs) were calculated to 
determine the association between the presence of 
at least one HLA-B*5701 and an ABC-HSR. All 
analyses were performed using the DerSimonian 
and Laird method under a random-effects model 
(24). Statistical heterogeneity was assessed using 
Q-statistic and I-squared tests (25). A p-value of ≤ 
0.10 indicated heterogeneity between studies.  I-
squared values of 25%, 50%, 75% denoted a low, 
moderate, and high of heterogeneity across 
studies, respectively (26).  Subgroup analyses 
based on ethnicity of the selected studies were 
performed to explore the sources of 
heterogeneity. A funnel plot, Begg’s test, and 
Egger’s test were used to evaluate publication 
bias (27,28). All statistical analyses were 
performed using the STATA software version 
11.0 (StataCorp., College Station, TX, USA). 
 
RESULTS 
 
Study Selection 
Of the 1,026 articles identified, 14 articles met the 
inclusion criteria (3,4,6,12-17,29-33). The studies 
of Mallal et.al. (31) and Martin et al. (6) 
contained the same data, consequently, the former 
was excluded. Three studies included Hughes 
et.al. (29), Rauch et.al. (32) and Colombo et.al. 
(33) did not provide enough information to 
perform statistical analysis, thus these studies 
were excluded. Hence ten studies were included 
in further meta-analysis (3,4,6,12-17,30) (Figure. 
1). No additional articles were identified in the 
bibliographies of the included studies. 
 
Study Characteristics 
Characteristics of the included studies are 
summarized in Table 1. All studies were case-
control studies (3,4,6,12-17,30). Five studies 
(3,12,14,16,30) used clinical manifestation alone 
as their diagnostic criteria. Whereas, five studies 
(4,6,13,15,17) used clinical manifestation and 
immunological testing to confirm the diagnosis 
ABC-HSR. Among those studies using clinical 
manifestations as their diagnostic criteria, 409 and 
1,883 subjects were included as cases and 
controls, respectively (3,4,12-16,30). In studies 
that used immunological testing to confirm their 
diagnostic criteria, 110 and 1,968 subjects were 
included as cases and controls, respectively 
(4,6,13,15,17). The populations of the included 
studies were summarized as shown in Table 1. In 
brief, there were white (8 studies) 
(3,4,6,12,13,15,17,30), black (5 studies) 
(3,4,15,16,30), Asian (1 study) (14) and other 
populations (1 study) (3). The mean ages of the 
patients were 41.8 and 41.6 years in cases and 
controls, respectively (3, 6, 12,13,15,17,30). 
Males comprised 86% of cases (127/148) and 
81% of controls (732/899) (3, 6, 12,17,30). In five 
studies (6,12-15), patients using abacavir for 6-52 
weeks without HSR were included in the control 
group, whereas patients demonstrating the 
symptoms within 6-10 weeks after commencing 
the abacavir therapy were classified into the case 
group (4,6,12,14,15,17).  Saag, et al. (15) reported 
the time to onset of HSR, noting that white 
patients and black patients demonstrated 
hypersensitivity within 17 and 32 days, 
respectively, after the initiation of abacavir 
therapy. Whereas, Stekler, et al. (13) reported the 
mean time to onset of ABC-HSR was 9 days. The 
included studies identified HLA-B*5701 using 
several distinct techniques: a high resolution 
DNA-based sequencing method (3,15,16), 
polymerase chain reaction (PCR) as a sequence 
based typing technique (14,17), PCR sequence-
specific oligonucleotides primers (4,6,13,30), or 
PCR-restriction fragment length polymorphism 
(12). No study provided enough information to 
calculate HWE.  
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Association between HLA-B*5701 and ABC-
HSR diagnosed by immunologic confirmation  
The data from 5 studies which identified ABC-
HSR by immunological confirmation 
 (4,6,13,15,17) were included. There were 110 
cases and 1,938 controls. In these studies, the 
numbers of patients carrying with at least on 
allele of HLA-B*5701 were 107 and 41 in cases 
and controls, respectively. Overall, the OR was 
1,056.2 (95% CI = 345.0 – 3,233.3; I2 = 0.00%, p 
= 0.64). In subgroup analysis based on ethnicity, 
the summary ORs were 1,113 (95% CI = 319.7-
3,875.1; I2 = 0.00%, p = 0.42) for whites 
(4,6,13,15,17) and 851.6 (95% CI = 67.9 – 
10,682.3; I2 = 0.0%, p = 0.00) for blacks (4,15), 
respectively (Figure 3). There was no apparent 
publication bias by the Begg test (P =0.29), Egger 
test (P = 0.72), or funnel plot. 
 
 
 
DISCUSSION 
 
Our results showed a strong association between 
the HLA-B*5701 and ABC-HSR where ABC-
HSR was confirmed by immunological testing. 
The OR was 1,056.2 (95% CI = 345.0 – 3,233.3). 
This strong association was similar to the results 
of the subgroup analyses in black and white 
population (Figure 3 and Table 2). Whereas, the 
ORs in the studies using clinical manifestation 
was 23.6 (95% CI = 15.4 – 36.3). The ORs among 
ethnicities (i.e. white, black, and Asian) were 
slightly different (Figure 2 and Table 2). 
Our results clearly indicated the superiority of 
immunological testing for ABC-HSR over 
clinical manifestation alone and the differing ORs 
for these groups probably results from the 
misclassification of ABC-HSR due to false-
positive diagnosis.  In the Mallal et al. study (4), a 
skin patch test provided exceptional sensitivity 
(100%) and specificity (96.9%).  
Figure 2 – Random-effects meta-analysis of clinically diagnosed ABC-HSR among HLA-B*5701-positive 
patients, stratified by ethnicity 
 
Thus, to increases the accuracy of ABC-HSR, 
immunological testing should supplement any 
clinical diagnosis of HSR. 
In the studies using clinical manifestation, the 
association between the HLA-B*5701 and ABC-
HSR was statistically significant in whites, blacks 
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and Asians. However, the association for “other” 
ethnicity group [i.e., mostly Hispanic 
(Hetherington, et al. study (3)] was not 
statistically significant (Figure 2 and Table 2). 
This might be due to 1) a small sample size and 2) 
less susceptibility to the HSR in the Hispanic 
population. In studies using immunological 
confirmation, the association between the HLA-
B*5701 and ABC-HSR was strong in whites and 
blacks (Figure 3).  
The Zucman, et al. study (30) was an 
observational study with 2 prominent objectives: 
1) to address the association between HLA-
B*5701 and ABC-HSR in a French population, 
and; 2) to re-evaluate the predictive value of 
HLA-B*5701 screening. It was divided into 2 
parts: part 1) was a retrospective study which 
tested HLA-B*5701 in patients previously 
exposed to abacavir; part 2) was a prospective 
study which pre-screened for HLA-B*5701 in 
abacavir-naive patients.  Thus, our analysis only 
extracted data from part 1. 
The study by Mallal, et al. (4) was a 
randomized control trial designed to establish the 
effectiveness of prospective HLA-B*5701 
immunological screening to prevent ABC-HSR. 
Patients in this study were randomly divided into 
2 groups.  For the first group, all patients received 
standard abacavir therapy before HLA-B*5701 
testing, whereas, subjects in the second group 
were pretested and those positive for the gene 
received no abacavir. We only extracted data 
from the first non-prescreened group and 
identified as a case-control study. Notably, the 
‘black’ population from Mallal et al. (4) also 
included American Indians or Alaskan natives 
(~8%), mixed (~8%) and other ethnicities 
(~11%). 
The results from the Mallal, et al. study (4) 
showed the incidence of ABC-HSR was 
significantly lowered in prospective HLA-B*5701 
screening group than those in the standard 
abacavir treatment. However, our results clearly 
demonstrated the association between HLA-
B*5701 and ABC-HSR especially in the studies 
used immunologic confirmation to identify ABC-
HSR (Figure 2 and Table 2).  
 Figure 3 - Random-effects meta-analysis of immunologic confirmation diagnosed ABC-HSR among HLA-B*5701-
positive patients, stratified by ethnicity 
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An emerging mechanism for abacavir action 
is by its specific steric binding via two unique 
amino-acid residues in the ‘F-pocket’ of HLA-
B*5701 protein, which results in the protein 
complexing with self-peptides of which about 
20% become recognized as non-self by CD8+T-
cells (9-11) and which elicits an ensuing 
autoimmune activation.  A similar modification of 
HLA-B*1502 also explained carbamazepine-
induced hypersensitivities (9). Nevertheless, 
abacavir-HLA-B*5701 penetrance was not 100%, 
and we show that the actual abacavir-induced 
hypersensitivity varied between white, Asian and 
black HLA-B*5701 carriers and a plausible 
explanation for this is maybe differing spectrums 
of self-tolerant peptides in the different 
populations or more likely different T-cell 
clonotypes which express a restricted range of the 
receptors responding to non-self antigens (34). 
The penetrance of abacavir-induced 
hypersensitivity in HLA-B*5701 individuals was 
about 50%, indicating that additional factors 
determine whether abacavir treatment induces 
abacavir-induced hypersensitivity (9). Thus, a 
polymorphism in HLA-B*5701 among the 
populations is possible. To prove this hypothesis, 
genetic sequencing studies of this particular gene 
in each population may be able to provide a better 
understanding in the difference in the abacavir-
induced hypersensitivity reaction. 
 
CONCLUSION  
 
Using meta-analysis, the association between 
HLA-B*5701 and ABC-HSR is strong in the 
studies using immunological confirmation to 
identify HLA-B*5701 and ABC-HSR. These 
results support the US FDA recommendations for 
screening HLA-B*5701 allele before beginning 
abacavir therapy.   
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Table 1 - Characteristics of included studies. 
Reference Study design Country Population 
Case Control 
 
Diagnostic method of  
ABC-HSR 
NOS HLA-B*5701  
positive (+) negative (-)  
+ - + - 
(3) Case-control UK 
White 36 29 1 79 
Clinical manifestation  4 Black 0 9 0 18 Other a 1 9 0 15 
(12) Case-control UK White 6 7 5 46 Clinical manifestation 4 
(6) b Case-control Australia White 17 1 4 226 Immunologic confirmation 5 
(13)d Case-control United States White 2 7 0 41 Clinical manifestation 6 2 2 0 41 Immunologic confirmation 
(14) Case-control Taiwan Asian 1 16 0 215 Clinical manifestation 4
(30) Case-control France White 6 7 0 27 Clinical manifestation 2 Black 0 3 0 6 
(4)d Case-control Australia 
White 29 32 19 638 Clinical manifestation
6 22 0 25 666 Immunologic confirmation 
Black c 1 4 0 124 Clinical manifestation 1 0 0 128 Immunologic confirmation
(15) d Case-control United States
White 57 72 8 194 Clinical manifestation 
6 42 0 8 194 Immunologic confirmation 
Black 10 59 2 204 Clinical manifestation5 0 2 204 Immunologic confirmation 
(16) Case-control Uganda Black 0 6 0 241 Clinical manifestation 3 
(17) Case-control Canada White 18 0 2 468 Immunologic confirmation 5
NOS = Newcastle-Ottawa Scale; a Including American Hispanic (84%) and other (6%); b This study provided only immunologic 
confirmation data; c Including Black (~73%), American Indian or Alaskan native (~8%), Mixed (~8%) and other (~11%); d These 
studied provided  both clinical manifestation and immunologic confirmation data. In case group, only some patients were confirmed 
by immunologic assay.   
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Table 2. Calculated odds ratio of the included studies and summary odds ration categorized by 
diagnostic methods od detecting hypersensitivity. 
Study Year 
HLA-B*5701positive/total Odds ratio 
(OR) 95% Confidence interval case control 
Clinical manifestation 
   White 
(3) 2002 36/65 1/80 98.07 12.85 - 748.24 
(12) 2004 6/13 5/51 7.89 1.89 - 32.91 
(13) 2006 2/9 0/41 27.67 1.20 - 635.62 
(30) 2007 6/13 0/27 47.67 2.40 - 945.62 
(4) 2008 29/61 19/657 30.43 15.44 - 59.99 
(15) 2008 57/129 8/202 19.20 8.73 - 42.21 
   Sub-total, I-squared = 4.1%, p = 0.390) 24.31 14.86 – 39.17 
   Black 
(4) 2008 1/5 0/124 83.00 2.95 - 23,332.67 
(15) 2008 10/69 2/206 17.29 3.69 - 81.09 
(30)  2007 0/3 0/6 NA NA 
(3)  2002 0/9 0/18 NA NA 
(16)  2011 0/6 0/241 NA NA 
   Sub-total, I-squared = 0.0%, p = 0.390 22.81 5.61 - 92.73 
   Asian 
 (14) 2007 1/17 0/215 39.18 1.54 - 999.98 
   Other 
(3)  2002 1/10 0/15 4.89 0.18 - 132.83 
Summary OR, I-squared = 0.0%, p= 0.6520 23.64 15.39 - 36.32 
Immunologic confirmation 
   White 
(6) 2004 17/18 4/230 960.50 101.64 - 9,077.14 
(13) 2006 2/4 0/41 83.00 3.08 - 2,236.28 
(4) 2008 22/22 25/691 1,176.18 69.40 - 19,934.93 
(15) 2008 42/42 8/202 1,945.00 110.12 - 34,352.38 
(17) 2012 18/18 2/470 6,933.80 321.33 - 149,621.53 
   Sub-total, I-squared=0.00%, p=0.418 1,112.96 319.65 - 3,875.11 
   Black 
(4) 2008 1/1 0/128 771.00 11.14 - 53,381.70 
(15) 2008 5/5 8/206 899.80 38.47 - 21,045.27 
Sub-total, I-squared=0.00%, p=0.953 851.62 67.89 - 10,682.31 
Summary OR, I-squared=0.00%, p=0.638 1,056.17 345.00 - 3,233.27 
